Jefferson researchers show chemotherapy and radiation together extend lung cancer patients' livesNovember 12, 2007(PHILADELPHIA) Chemotherapy given at the same time as radiation therapy can help patients with a certain type of lung cancer live nearly 50 percent longer than they might have otherwise if the same treatment was given differently, according to an international team's analysis of several trial results. Walter Curran Jr., M.D., professor and chair of Radiation Oncology at Jefferson Medical College of Thomas Jefferson University and Jefferson's Kimmel Cancer Center in Philadelphia, led one of six trials comparing the effectiveness of giving chemotherapy at the same time as radiation therapy versus giving radiation first, followed later by chemotherapy, to treat locally advanced non-small cell lung cancer (NSCLC). According to Dr. Curran, there had been some controversy over whether simultaneous administration of chemotherapy and radiation for such cases was better than sequential delivery. In the United States, chemotherapy and radiation together have become the standard, whereas in other areas, such as Europe, for example, this has not been the case. To try to resolve the matter, the International NSCLC Collaborative Group examined the results of more than 1,200 patients from six trials. The researchers found that the five-year survival rate was 10.6 percent with sequential therapy, while 15.1 percent with concurrent treatment. Dr. Curran presented the results recently at the meeting of the American Society for Therapeutic Radiology and Oncology in Los Angeles. "That means a relative increase of nearly 50 percent," notes Dr. Curran, who led the Radiation Therapy Oncology Group (a Philadelphia-based cooperative clinical trials organization) trial. "We've demonstrated that the magnitude of benefit is observable in many studies, regardless of the regimen. I think it will be as persuasive as any data that this will change not only the tumor control rate but the chance for a long-term cure." Dr. Curran explains that the only difference in the two treatments is that radiation is begun at another time. The drugs and radiation techniques are the same. "You're changing the first day of radiation from day 40 to day one, for example, and as a result, are changing the number of five-year survivors by between 40 percent and 50 percent," he says. According to these findings, theoretically, if there were 50,000 patients, approximately 5,000 who received sequential therapies would be alive in five years, and with concurrent, about 7,500. "It is a new standard of care," he says about the results. "It's relatively broadly adopted in this country, but across the world, it hasn't been. This will be a very persuasive argument." Thomas Jefferson University |
|||||||||||||||||||||
| Related Chemotherapy Current Events and Chemotherapy News Articles First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Chemo-radiation before prostate removal may prevent cancer recurrence Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. PMH finding may help some tonsil cancer patients avoid chemotherapy Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Blood vessels might predict prostate cancer behavior A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? Discovery offers potential new pancreatic cancer treatment Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. Early-stage, HER2-positive breast cancer patients at increased risk of recurrence Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. An exquisite container In campy old movies, Lucretia Borgia swans around emptying powder from her ring into wine glasses carelessly left unattended. The poison ring is usually a confection of gold filigree holding a cabochon or faceted gemstone that can be broken to empty the ring's contents. It is invariably enormous - so large it is rather odd nobody seems to notice it. Duke develops nano-scale drug delivery for chemotherapy Going smaller could bring better results, especially when it comes to cancer-fighting drugs. More Chemotherapy Current Events and Chemotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||